NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Related Editorial The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs. Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling…







